诱导方法对多药耐药细胞系A549/Gem建立的影响  

Inducement's impacts on establishment of multi-drug-resistant cell line A549/Gem

作　　者：王伟霞[1] 刘晓晴[1] 刘广贤[1] 佟雅丽[1] 陈建魁[1] 朱运峰[1] 汤传昊[1] 王维威[1] 

机构地区：[1]军事医学科学院附属医院全军肿瘤中心肺癌内科,北京100071

出　　处：《现代肿瘤医学》2009年第11期2058-2062,共5页Journal of Modern Oncology

基　　金：首都医学发展基金(No.2003-3028)

摘　　要：目的:探讨诱导方法对多药耐药细胞系A549/Gem建立的影响。方法:以A549细胞为原代细胞,采用4种方法,建立多药耐药细胞系A549/Gem-1、A549/Gem-2、A549/Gem-3和A549/Gem-4(统称A549/Gem)。比较其诱导前后耐药指数和耐药谱、形态学特征、倍增时间、细胞周期分布及TPS、SCC、CEA、CY-FRA21-1、ERCC1和RRM1mRNA表达的变化。结果:4种细胞对吉西他滨的耐药指数分别为38.277、12.268、115.297和25.679,均获得多药耐药性,但耐药谱差别较大。其中,A549/Gem-1和A549/Gem-4细胞的G0-G1期细胞比例较A549细胞降低。A549/Gem细胞的倍增时间较A549细胞缩短,形态学变化显著,CEA、TPS、SCC和CYFRA21-1表达变化不大,RRM1和ERCC1mRNA相对表达量增多。结论:A549/Gem细胞获得多药耐药性,诱导方法对其建立影响较大。Objective：To study the impacts of inductive method on establishment of multi - drug - resistant cell line A549/Gem. Methods： Multi - drug - resistant cell line A549/Gem included A549/Gem - 1, A549/Gem - 2, A549/Gem- 3 and A549/Gem -4 was established in four different methods from its parental cell line. To compare the resistance index and resistant pedigree, morphologic character, doubling time, the distribution of cell cycle, the expression of TPS, SCC, CEA, CYFRA21 - 1, ERCC1 and RRM1 mRNA between A549 and A549/Gem cells. Results： The resistance indexes to gemcitabine of four different cell lines bearing different resistant pedigree were 38.277, 12. 268,115. 297 and 25. 679 respectively. And the proportions in G0 - G1 phase of A549/Gem - 1 and A549/Gem - 4 ceils were reduced than A549 cells. The doubling time of A549/Gem cells was shorter than A549 cells, at the same time they exhibited distinctive morphologic character. The expression of CEA,TPS,SCC and CYFRA21 - 1 in A549/ Gem and ASd9 cell lines had no significant difference. But the levels of RRM1 and ERCC1 mRNA in A549/Gem cells were higher than A549 cells. Conclusion：The cell line A549/Gem had acquired multi - drug resistance. The inductive method affected markedly the establishment of it.

关 键 词：诱导 细胞系 吉西他滨 多药耐药 肿瘤标志物 基因 

分 类 号：R730.53[医药卫生—肿瘤]